Nanoradox – Melanoma and non Melanoma skin cancers - Vision Oncology

Nanoradox is a Class III medical device that, in in-vivo studies, shows an inhibition of the growth of the tumor mass by over 50%.

Nanoradox is a non-invasive, non-toxic hyperemic treatment that can support pharmacological therapies. It is essential for extending patients’ lives and significantly increasing their quality of life during and after the illness.

Second indication: Nanoradox – Melanoma and non Melanoma skin cancers*

4th

MOST COMMON CANCER
GLOBALLY

1.198.000

NEW CASES
EVERY YEAR

121.000

DEATHS
EVERY YEAR

> 90 %

5 YEARS
SURVIVAL RATE

* Source: Sung H, Ferlay J, Siegel R L et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians 2021; 71: 209-249.

Melanoma and non melanoma skin cancers

Nonmelanoma skin cancer refers to all the types of cancer that occur in the skin that are not melanoma. Several types of skin cancer fall within the broader category of nonmelanoma skin cancer, with the most common types being basal cell carcinoma and squamous cell carcinoma. Nonmelanoma skin cancer treatment depends on the type of cancer. Skin cancer treatment usually involves surgery to remove the cancer cells.

Melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control. Melanoma is much less common than some other types of skin cancers, but it is more dangerous because it’s much more likely to spread to other parts of the body if not found and treated early.

Nanoradox – Melanoma and non Melanoma skin cancers - Vision Oncology

How Nanoradox works

* This image is just a render and can not correspond to the actual machine

Hyperthermia destroys the tumor mass

Each session consists of three treatments over three consecutive days.

Nanoradox - Vision Oncology

Our roadmap